Niemann-Pick type C (NPC) disease is a lysosomal storage disease in which endocytosed cholesterol becomes sequestered in late endosomes/lysosomes (LEs/Ls) because of mutations in either the NPC1 or NPC2 gene. Mutations in either of these genes can lead to impaired functions of the NPC1 or NPC2 proteins and progressive neurodegeneration as well as liver and lung disease. NPC1 is a polytopic protein of the LE/L limiting membrane, whereas NPC2 is a soluble protein in the LE/L lumen. These two proteins act in tandem and promote the export of cholesterol from LEs/Ls. Consequently, a defect in either NPC1 or NPC2 causes cholesterol accumulation in LEs/Ls. In this review, we summarize the molecular mechanisms leading to NPC disease, particularly in the CNS. Recent exciting data on the mechanism by which the cholesterol-sequestering agent cyclodextrin can bypass the functions of NPC1 and NPC2 in the LEs/Ls, and mobilize cholesterol from LEs/Ls, will be highlighted. Moreover, the possible use of cyclodextrin as a valuable therapeutic agent for treatment of NPC patients will be considered.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109756 | PMC |
| http://dx.doi.org/10.1194/jlr.R047837 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical manifestations and molecular genetics of seven patients with Niemann-Pick type-C: a case series with a novel variant.
J Pediatr Endocrinol Metab
January 2025
Department of Pediatric Metabolism and Ankara University Rare Diseases Application and Research Center, Ankara University Faculty of Medicine, Ankara, Türkiye.
Objectives: Niemann-Pick type C (NPC) is a rare, autosomal recessive, neurodegenerative disorder caused by biallelic pathogenic variants in the or genes, leading to lysosomal lipid accumulation. NPC has an incidence of 1 in 100,000 live births and presents with a wide range of symptoms affecting visceral organs and the central nervous system. We aim to describe the diverse clinical presentations of NPC through case studies.
View Article and Find Full Text PDFLysosomal damage due to cholesterol accumulation triggers immunogenic cell death.
Autophagy
December 2024
Centre de Recherche des Cordeliers, INSERM UMRS 1138, Sorbonne Université, Université Paris Cité, Équipe labellisée par la Ligue contre le Cancer, Institut Universitaire de France, Paris, France.
Cholesterol serves as a vital lipid that regulates numerous physiological processes. Nonetheless, its role in regulating cell death processes remains incompletely understood. In this study, we investigated the role of cholesterol trafficking in immunogenic cell death.
View Article and Find Full Text PDFInvestigating p.Ala1035Val in NPC1: New Cellular Models for Niemann-Pick Type C Disease.
Int J Mol Sci
November 2024
Research and Development Unit, Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge (INSA, I. P.), Rua Alexandre Herculano 321, 4000-055 Porto, Portugal.
Article Synopsis
- * The p.Ala1035Val variant is the most common in Portugal and is linked to a potential SNP (p.Ile858Val) that may affect disease progression.
- * Research using in vitro models reveals that the p.Ala1035Val variant, especially when combined with p.Ile858Val, shows decreased lysosomal trafficking similar to p.Ile1061Thr, suggesting the need for new therapeutic approaches.
Infantile Cholestatic Jaundice: A Variant of Niemann-Pick Disease Type C2.
Cureus
September 2024
Paediatrics, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, IND.
Niemann-Pick disease is an autosomal recessive lysosomal lipid storage disorder disease caused by mutations in either Niemann-Pick disease type C1 (NPC1) or the NPC2 gene. It has a wide range of symptoms that vary in severity, classified into three main types: A, B, and C1 and C2, based on genetics and the symptoms and signs. The usual presentation in the neonatal period is cholestatic jaundice, subsequently, it will develop hepatosplenomegaly in infancy, failure to thrive, ataxia, hypotonia, seizure, difficulty in speech, swallowing, and recurrent respiratory tract infection.
View Article and Find Full Text PDFMolecular determinants of phospholipid treatment to reduce intracellular cholesterol accumulation in NPC1 deficiency.
J Biol Chem
November 2024
Department of Nutritional Sciences, Rutgers University, New Brunswick, New Jersey, USA; Rutgers Center for Lipid Research, Rutgers University, New Brunswick, New Jersey, USA. Electronic address:
Article Synopsis
- - Niemann-Pick type C (NPC) disease results from mutations in NPC1 or NPC2 genes, leading to the accumulation of cholesterol in late endosomes/lysosomes, and researchers are exploring LBPA (lysobisphosphatidic acid) as a therapeutic agent to reduce this accumulation.
- - Studies indicate that different stereoisomers of LBPA are effective in reducing cholesterol levels in NPC1-deficient human fibroblast cells, with the presence of an 18:1 acyl chain being particularly significant for enhancing cholesterol clearance.
- - Further experiments suggest that while phosphatidylglycerol (PG) can also reduce cholesterol, it does not convert to LBPA effectively, highlighting that LBPA itself is essential for promoting cholesterol
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!